Professor Marta Weinstock-Rosin, Ph.D.
Professor Weinstock-Rosin, co-inventor of Ladostigil, is Professor Emeritus at the Hebrew University, Jerusalem, Israel. She was Chairperson of the Department of Pharmacology from 1983-1986, and President of the Israel Society for Neuroscience from 2003-2005. She was awarded the Kaye prize for the invention of Exelon in 2000 and was the first person working in a University to be awarded a prize by the Institute of Ageing, USA for inventing Rivastigmine (Exelon®, Novartis Pharmaceuticals), a drug for the treatment of Alzheimer’s Disease.
Professor Weinstock-Rosin has co-authored more than 200 research papers, invited reviews and book chapters, and supervised more than 50 postgraduate students for their M.D., M.Sc. and Ph.D. studies. She has served on the Editorial board of Journals of Pharmacology and of Neuroscience, numerous University Committees and the Board of the Israel Society for Psychobiology.
Professor Moussa B.H. Youdim, Ph.D.
Professor Youdim, co-inventor of Ladostigil, is Professor Emeritus at the Technion Israel Institute of Technology in Haifa, Israel. He is also Director of the Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research.
Professor Youdim is a world expert in neurodegenerative disease research, and has been associated with the development of successful drugs during his career including Selegiline, and Rasagiline (Azilect®). He has published more than 800 peer-reviewed and invited articles, 45 books and more than 300 review articles. He has served or is serving on the editorial boards of 43 international journals of neurochemistry, pharmacology, neuropharmacology and neuropsychiatry, and has received more than 50 national and international awards.
Professor Michael Chorev, Ph.D.
Professor Michael Chorev, co-inventor of Ladostigil, retired from the Hebrew University where he held the Drs. Margaret and Henry Zentner chair of Pharmaceutical Chemistry. He is currently a faculty member of the Laboratory for Translational Research at the Harvard Medical School and affiliated with the Department of Medicine at Brigham and Women’s Hospital. He is the co-inventor of Rivastigmine (Exelon®).
Professor Chorev has co-authored over 170 scientific articles and reviews in journals, chapters in monographs and books. He has mentored close to 30 postgraduate students for their M.Sc., Ph.D. studies and post-doctoral training, and has served as a member of the Editorial Board of the Journal of Peptide Research and Biopolymers and is an Editor for Journal of Peptide Science. Professor Chorev received his B.Sc., M.Sc. and Ph.D. from the Hebrew University and did his Post-doctoral training at University of California, San Diego.